Biocentury: Regeneron Using Interleukin Antibody Receptors for Asthma Medication
An estimated 25 million Americans suffer from Asthma, but current medications such as inhalers have been deemed ineffective for 10-20% of its users. Regneron (REGN) and Sanofi (SAN) have partnered to crease a new Asthma drug, Dupilumab.
Read more »Inhalable Drugs Let Patients Take a Breather from Needles
Earlier this month, a team of researchers led by the University of Colorado at Boulder announced that the inhalable measles vaccine they developed could lead to vaccines for other diseases.
Read more »As Seasonal Flu Ramps Up, NexBio Begins Phase II Trial for DAS181
DAS181 is formulated to prevent the influenza virus from entering cells in the respiratory tract.
Read more »Researchers Identify Gene Linked to Childhood Asthma
U.S. researchers have identified a gene that is linked to childhood asthma.
Read more »NeoPharm Tipped As Stock to Watch
NeoPharm, a biopharmaceutical company developing drugs for cancer treatment, has been tipped as a worthwhile stock on financial website Seeking Alpha.
Read more »